Drug intelligence / Profile preview

diazepam + indomethacin

Development stage
Unknown
Lead developer
Roche
Modality
Small Molecules
Administration
Oral, Rectal
01

Overview

Diazepam + indomethacin is a combination of two pharmaceutical agents used together, particularly for the management of night pain and morning stiffness in patients with active rheumatoid arthritis. Diazepam is a long-acting benzodiazepine that acts as an anxiolytic, muscle relaxant, and sedative by enhancing the effect of gamma-aminobutyric acid (GABA) at the GABA-A receptor in the central nervous system. Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) that exerts its effects primarily through inhibition of cyclooxygenase enzymes (COX-1 and COX-2), leading to decreased synthesis of prostaglandins involved in inflammation, pain, and fever. The combination has been shown to provide superior control over night pain and morning stiffness compared to indomethacin alone in rheumatoid arthritis patients[1][2]. Both drugs may cause dizziness as an additive side effect when used together[5][10].

02

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)GABRA1 (Gamma-aminobutyric acid type A receptor alpha 1 subunit)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on diazepam + indomethacin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on diazepam + indomethacin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call